Starling Oncology (STLNW) Cash & Current Investments (2019 - 2026)

Starling Oncology (STLNW) has reported Cash & Current Investments for 8 consecutive years, with $41.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 35.66% year-over-year to $41.1 million; the trailing twelve-month figure through Jun 2026 stood at $41.1 million (up 35.66% YoY), and the FY2025 full-year result was $33.6 million, down 32.42% from the prior year.
• Cash & Current Investments improved to $41.1 million in Q2 2026 per STLNW's latest filing, from $30.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $95.5 million in Q1 2022 and bottomed at $27.7 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $55.6 million across 5 years, with a median of $48.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments soared 685.46% in 2022, then plunged 45.77% in 2024.
• Over 5 years, Cash & Current Investments stood at $73.8 million in 2022, then gained by 12.26% to $82.9 million in 2023, then slumped by 40.05% to $49.7 million in 2024, then plunged by 32.42% to $33.6 million in 2025, then gained by 22.43% to $41.1 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $41.1 million, $30.3 million, and $33.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.